Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study)
Status:
Completed
Trial end date:
2017-09-12
Target enrollment:
Participant gender:
Summary
Late-life depression is characterized by both affective (mood) symptoms and cognitive
deficits. There is currently no intervention that may provide consistent benefits to both
mood and cognitive performance. Agonist activity at the nicotinic acetylcholine receptors via
transdermal nicotine patches may provide benefit to both mood and cognition, working through
nicotine's effects on brain neural networks, specifically the cognitive control network and
default mode network.
In this initial pilot project, the investigators will test this hypotheses in 15 nonsmoking
depressed elders with subjective cognitive impairment. Following baseline neuroimaging and
cognitive testing, participants will receive 12 weeks of open-label transdermal nicotine.
Afterwards, participants will repeat neuroimaging and cognitive assessments.
Phase:
Phase 4
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center